Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides

Inclusion Criteria: * Documentation of diagnosis as evidenced by one or more clinical features consistent with mycosis fungoides cutaneous T-cell lymphoma * Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with requirements of the study * Skin biopsy specimen of representative lesion obtained at screening of study and deemed diagnostic of mycosis fungoides by principal investigator * Mycosis fungoides patients that have stage T2-4 N0-1 M0B0 disease * Availability of subject to be observed for up to 18 months post-screening evaluation * Life expectancy greater than 6 months Exclusion Criteria: * Pregnant or breast-feeding females * Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data * Patients diagnosed with Sezary syndrome; Sezary syndrome is equivalent to mycosis fungoides that develops to stage IVA/B with B2 (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT * Underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to undergo treatment * Minimum 3 weeks since prior systematic treatment or phototherapy * Exclusion of people that do not understand the risks, such as decisionally-impaired individuals, prisoners, and vulnerable populations